On Friday, Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) opened higher 8.00% from the last session, before settling in for the closing price of $3.00. Price fluctuations for ZNTL have ranged from $2.66 to $18.07 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 45.10% at the time writing. With a float of $57.60 million, this company’s outstanding shares have now reached $71.15 million.
Let’s look at the performance matrix of the company that is accounted for 168 employees. In terms of profitability, gross margin is 97.68%, operating margin of -490.5%, and the pretax margin is -419.76%.
Zentalis Pharmaceuticals Inc (ZNTL) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Zentalis Pharmaceuticals Inc is 19.17%, while institutional ownership is 83.17%. The most recent insider transaction that took place on Jan 02 ’25, was worth 13,762. In this transaction Chief Scientific Officer of this company sold 4,411 shares at a rate of $3.12, taking the stock ownership to the 191,317 shares. Before that another transaction happened on Oct 31 ’24, when Company’s Former Chief Medical Officer proposed sale 9,888 for $2.86, making the entire transaction worth $28,294.
Zentalis Pharmaceuticals Inc (ZNTL) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 45.10% per share during the next fiscal year.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Trading Performance Indicators
Check out the current performance indicators for Zentalis Pharmaceuticals Inc (ZNTL). In the past quarter, the stock posted a quick ratio of 7.29. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.15.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.53, a number that is poised to hit -0.79 in the next quarter and is forecasted to reach -2.93 in one year’s time.
Technical Analysis of Zentalis Pharmaceuticals Inc (ZNTL)
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) saw its 5-day average volume 1.48 million, a positive change from its year-to-date volume of 1.31 million. As of the previous 9 days, the stock’s Stochastic %D was 55.02%. Additionally, its Average True Range was 0.27.
During the past 100 days, Zentalis Pharmaceuticals Inc’s (ZNTL) raw stochastic average was set at 20.86%, which indicates a significant decrease from 83.18% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.14% in the past 14 days, which was lower than the 88.49% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.32, while its 200-day Moving Average is $6.26. Nevertheless, the first resistance level for the watch stands at $3.38 in the near term. At $3.51, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.70. If the price goes on to break the first support level at $3.06, it is likely to go to the next support level at $2.87. The third support level lies at $2.74 if the price breaches the second support level.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Key Stats
There are currently 71,265K shares outstanding in the company with a market cap of 249.37 million. Presently, the company’s annual sales total 0 K according to its annual income of -292,190 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -88,280 K.
